Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia

Clinical trial NCT03913559 · TERMINATED

Trial details

NCT number: NCT03913559
Sponsor: St. Jude Children's Research Hospital
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia

Start date: 2019-05-14
Primary completion: 2025-09-15
Enrollment: 5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.